SIBN

23.7300.08%
MN

Mika Nishimura

Independent Director

Ms. Mika Nishimura is an Independent Director of NEC Corporation from June 2025. Ms. Mika Nishimura serves as an Operational Partner at Gilde Healthcare Partners US Inc and focuses on Venture&Growth at the firm. She serves as Independent Director at HOYA Corporation since June 2022. She serves as an Operational Partner at Gilde Healthcare Partners B.V. since 2011. She serves as an Independent Director of Accuray Incorporated since August 17, 2021. She From 2016 to April 2020, Ms. Nishimura was Vice President, Commercialization at nVision Medical Corporation. From April 2011 to 2015, Ms. Nishimura was Vice President, Commercial Development for Auxogyn, Inc. In her career, she was Director of Global Marketing at Guidant Vascular Intervention and Vice President, International Sales Operations and Marketing at ev3, Inc., she started and built franchises contributing significant, consistent revenue and profit growth with operations in several markets. She serves as a Vice President of Commercial Development at Progyny, Incorporated (formerly Auxogyn, Inc.). Ms. Nishimura joined Auxogyn in April 2011. Prior to Auxogyn, Ms. Nishimura founded and built The BLG Group, a successful consulting practice advising both investors and device companies on critical strategic initiatives. She serves as Vice President of Commericialization at nVision Medical Corporation. Prior to joining nVision in 2015, Ms. Nishimura drove early commercialization of a first-of-a-kind diagnostic technology in the IVF field at Auxogyn, Incorporated as their Vice President Commercial Development. Her previous positions include Vice President of International Sales, Operations and Marketing at ev3 and Director of Marketing at Guidant Vascular where she started and built franchises contributing significant, consistent revenue and profit growth with operations in over 30 markets. In 1999, Ms. Nishimura founded The BLG Group. Her clients have sought her group’s advice on critical strategic initiatives ranging from identifying high-priority acquisition targets, developing a product and technology road map based on rigorous analyses and strategic thinking, or creating and executing a geographical expansion plan. She is a frequent speaker at medical device and life science conferences. She is a seasoned senior executive with leadership experience in medical device industry. She serves as an Independent Director of SI-BONE, Inc. since March 4, 2021. She joined the SI-BONE, Inc. on March 04, 2021. Ms. Nishimura is an independent board member for MobileODT, a commercial-stage Israeli company and is also a board advisor to Tristel, plc since January 2021. Ms. Nishimura holds an M.B.A. from the Harvard Graduate School of Business Administration and a B.A. in Economics with distinction, summa cum laude from Yale University.

Positions